Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
The findings suggest that beta-blockers and other drugs that help restore balance to the autonomic nervous system may have ...
Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...
The first patient has begun treatment on a global trial of a novel medication for Huntington's disease, led within the UK by ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the ...
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in ...
Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Common symptoms of Huntington's include uncontrolled movements like jerking and twitching, loss of coordination, difficulty ...
The Wicked Witch of the West and I have something in common: We both use our fatal flaws to our advantage—for her, her green ...
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
Beta-blocker drugs -- commonly used to treat heart and blood pressure issues -- may slow the progression of Huntington's disease (HD), according to a new study.